Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
About this item
Full title
Author / Creator
Steinman, Lawrence , Fox, Edward , Hartung, Hans-Peter , Alvarez, Enrique , Qian, Peiqing , Wray, Sibyl , Robertson, Derrick , Huang, DeRen , Selmaj, Krzysztof , Wynn, Daniel , Cutter, Gary , Mok, Koby , Hsu, Yanzhi , Xu, Yihuan , Weiss, Michael S. , Bosco, Jenna A. , Power, Sean A. , Lee, Lily , Miskin, Hari P. and Cree, Bruce A.C.
Publisher
Boston: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Boston: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In two parallel randomized trials in patients with MS, ublituximab resulted in lower relapse rates and fewer brain lesions on MRI than teriflunomide over a period of 96 weeks but did not affect disability.
Alternative Titles
Full title
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2706717768
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2706717768
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa2201904
